Page 5 - Celero Systems News Today : Breaking News, Live Updates & Top Stories | Vimarsana

2Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 3Associate Editor, JAMA 4Department of Community Health Sciences, Boston University School of Public Health, and Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Grayken Center for Addiction, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts JAMA. Published online February 25, 2021. doi:10.1001/jama.2021.0958

On January 14, 2021, days before a change in presidential administrations, the US Department of Health and Human Services (HHS) announced a plan to publish Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder “pursuant to 21 USC §823(g)(2)(H)(i)(II),” a provision of the Drug Addiction and Treatment Act of 2000 (DATA 2000). 1 This announcement caused a mix of enthusiasm, skepticism, and confusion in the medical community, and the retraction of the plan to publish the guideline less than 2 weeks later by the Biden administration has created an opport...